Armodafinil
Talk0this wiki
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology
|
Armodafinil chemical structure | |
| (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide IUPAC name | |
| CAS number 68693-11-8 | ATC code |
| PubChem [1] | DrugBank [2] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 273.351 |
| Bioavailability | |
| Metabolism | Hepatic, including CYP3A4 and other pathways |
| Elimination half-life | 12-15 hrs |
| Excretion | Urine (as metabolites) |
| Pregnancy category | C |
| Legal status | Schedule IV (USA) |
| Routes of administration | Oral |
Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., currently in the process of receiving Food and Drug Administration (FDA) approval. Armodafinil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer duration of time than modafinil. Cephalon hopes to soon release the longer-lasting Nuvigil (R-modafinil) as a "truly once-a-day" wakefulness medication. In 2006, the FDA sent Cephalon an "approvable letter" for Nuvigil, pending agreement on the final product labeling. Upon approval, it is expected to be classified as a Schedule IV controlled substance.
See also
Edit
External links
Edit
- gl:Armodafinil
| This page uses Creative Commons Licensed content from Wikipedia (view authors). |